Molecular imaging in oncology:18F-sodium fluoride PET imaging of osseous metastatic disease

American Journal of Roentgenology

Volumn 203, Issue 2, 2014, Pages 263-271

  Mick, Curtis G ^a   James, Trent ^a   Hill, Jacqueline D ^a   Williams, Patrick ^a   Perry, Mark ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Bone metastasis; Cancer staging; Oncology; PET; Sodium fluoride

Indexed keywords

BONE METASTASIS; CANCER STAGING; ONCOLOGY; PET; SODIUM FLUORIDE;

BONE NEOPLASMS; FLUORINE RADIOISOTOPES; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SODIUM FLUORIDE; TECHNETIUM TC 99M MEDRONATE;

EID: 84906501233     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.13.12158     Document Type: Review

References (69)

1. Chua S, Gnanasegaran G, Cook GJ. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases. Semin Nucl Med 2009; 39:416-430
2. 18F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol 2012; 14:252-259
3. Podoloff DA, Ball DW, Ben-Josef E, et al. NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw 2009; 7(suppl 2):S1-S26
4. Savelli G, Maffioli L, Maccauro M, De Deckere E, Bombardieri E. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med 2001; 45:27-37 (Pubitemid 32586339)
5. 18F-FDG PET/CT for diagnosis of osteosclerotic and osteolytic vertebral metastatic lesions: comparison with bone scintigraphy. Asian Spine J 2013; 7:96-103
6. 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases. Rev Esp Med Nucl 2011; 30:94-96
7. Schirrmeister H, Guhlmann A, Elsner K, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med 1999; 40:1623-1629 (Pubitemid 29471151)
8. Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med 1962; 3:332-334
9. Vallabhajosula S, Solnes L, Vallabhajosula B. A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: what is new? Semin Nucl Med 2011; 41:246-264
10. 18F bone scintigraphy: basic principles, advanced imaging concepts, and case examples. J Nucl Med Technol 2007; 35:64-76
11. 18F-fluoride: applying new technology to an old tracer. J Nucl Med 2008; 49:68-78
12. Dahlbom M, Hoffman EJ, Hoh CK, et al. Wholebody positron emission tomography. Part I. Methods and performance characteristics. J Nucl Med 1992; 33:1191-1199
13. Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun 2008; 29:193-207 (Pubitemid 351499295)
14. 18F] fluoride ion and PET. J Comput Assist Tomogr 1993; 17:34-41
15. 18F-fluoride PET/CT in benign and malignant bone diseases. Bone 2012; 50:128-139
16. Langsteger W, Haim S, Knauer M, et al. Imaging of bone metastases in prostate cancer: an update. Q J Nucl Med Mol Imaging 2012; 56:447-458
17. Cook GJ. PET and PET/CT imaging of skeletal metastases. Cancer Imaging 2010; 10:153-160
18. 18F-NaF deposition. J Nucl Med 2010; 51:1826-1829
19. 18F-fluoride PET/CT bone scans 1.0. J Nucl Med 2010; 51:1813-1820
20. 18F-Fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med 2007; 37:462-469
21. 18F in rabbit bone. Clin Sci Mol Med 1974; 47:73-77
22. International Commission on Radiological Protection. Radiation dose to patients from radiopharmaceuticals (addendum to ICRP publication 53): ICRP publication 80. Ann ICRP 1998; 28(3)
23. 18F-FDG. Radiat Prot Dosimetry 2010; 139:208-213
24. Hetzel M, Arslandemir C, Konig HH, et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res 2003; 18:2206-2214 (Pubitemid 37463314)
25. 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001; 42:1800-1804
26. 18F-fluoride PET/CT. J Nucl Med 2006; 47:287-297
27. 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma. Clin Nucl Med 2013; 38:616-621
28. Yen RF, Chen CY, Cheng MF, et al. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. Nucl Med Commun 2010; 31:637-645
29. 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2009; 36:1807-1812
30. Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999; 17:2381-2389 (Pubitemid 29368236)
31. 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun 2011; 32:168-176
32. 99mTc-MDP bone scan. Jpn J Radiol 2013; 31:262-269
33. 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases. Clin Nucl Med 2013; 38:e290-e296
34. 18F-NaF) position emission tomography (PET) in the evaluation of altered osteogenic activity. Bethesda, MD: National Institutes of Health, 2009
35. 18F-fluoride measured with positron emission tomography in correlation with CT. Skeletal Radiol 1998; 27:72-76
36. Bhargava P, Hanif M, Nash C. Whole-body F-18 sodium fluoride PET-CT in a patient with renal cell carcinoma. Clin Nucl Med 2008; 33:894-895
37. Weber DA, Greenberg EJ, Dimich A, et al. Kinetics of radionuclides used for bone studies. J Nucl Med 1969; 10:8-17
38. Caldarella C, Treglia G, Giordano A, Giovanella L. When to perform positron emission tomography/ computed tomography or radionuclide bone scan in patients with recently diagnosed prostate cancer. Cancer Manag Res 2013; 5:123-131
39. 18F-fluoride positron emission tomography for assessment of metastatic bone tumor. Ann Nucl Med 2010; 24:523-531
40. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med 2005; 46:1356-1367 (Pubitemid 43733488)
41. 18F-FDG. Nucl Med Rev Cent East Eur 2011; 14:105-108
42. Jadvar H. Molecular imaging of prostate cancer: PET radiotracers. AJR 2012; 199:278-291
43. Donohoe KJ, Brown ML, Collier BD, et al. Society of Nuclear Medicine procedure guideline for bone scintigraphy. Society of Nuclear Medicine website. interactive.snm.org/index.cfm?PageID=1110&Fil. Published June 20, 2003. Accessed October 2013
44. 18F-sodium fluoride time-of-flight PET of diagnostic quality? Nucl Med Commun 2013; 34:417-425
45. 18F-fluoride PET/CT. J Nucl Med 2004; 45:272-278
46. Willowson KP, Bailey EA, Bailey DL. A retrospective evaluation of radiation dose associated with low dose FDG protocols in whole-body PET/CT. Australas Phys Eng Sci Med 2012; 35:49-53
47. Xia T, Alessio AM, De Man B, Manjeshwar R, Asma E, Kinahan PE. Ultra-low dose CT attenuation correction for PET/CT. Phys Med Biol 2012; 57:309-328
48. Montes C, Tamayo P, Hernandez J, et al. Estimation of the total effective dose from low-dose CT scans and radiopharmaceutical administrations delivered to patients undergoing SPECT/CT explorations. Ann Nucl Med 2013; 27:610-617
49. Freeman RK, Dilts JR, Ascioti AJ, Giannini T, Mahidhara RJ. A comparison of quality and cost indicators by surgical specialty for lobectomy of the lung. J Thorac Cardiovasc Surg 2013; 145:68-74
50. Kalathiya RJ, Saha SP. Pneumonectomy for non-small cell lung cancer: outcomes analysis. South Med J 2012; 105:350-354
51. Uematsu T, Yuen S, Yukisawa S, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR 2005; 184:1266-1273 (Pubitemid 43821911)
52. 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med 2005; 19:573-579
53. Gallowitsch HJ, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose positron emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 2003; 38:250-256 (Pubitemid 36535030)
54. 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16:3375-3379
55. 18F-fluorodeoxyglucose positron emission tomography. Q J Nucl Med 2001; 45:47-52
56. Cook GJ, Fogelman I. The role of positron emission tomography in skeletal disease. Semin Nucl Med 2001; 31:50-61 (Pubitemid 32060652)
57. Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. Semin Nucl Med 2005; 35:135-142 (Pubitemid 40568746)
58. Nakai T, Okuyama C, Kubota T, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005; 32:1253-1258 (Pubitemid 41598715)
59. Cook GJ, Fogelman I. Skeletal metastases from breast cancer: imaging with nuclear medicine. Semin Nucl Med 1999; 29:69-79 (Pubitemid 29061432)
60. Talbot JN, Paycha F, Balogova S. Diagnosis of bone metastasis: recent comparative studies of imaging modalities. Q J Nucl Med Mol Imaging 2011; 55:374-410
61. 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 2006; 36:73-92
62. 18F-FDG PET/CT in the detection of bony metastases in heightened-risk head and neck cancer patients. J Nucl Med 2012; 53:1730-1735
63. 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med 2012; 37:637-643
64. 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med 2009; 50:501-505
65. Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser EA, Nitzsche EU. Combined FDG and [F18]fluoride whole-body PET: a feasible two-inone approach to cancer imaging? Radiology 1998; 209:253-258 (Pubitemid 28464675)
66. 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial. J Nucl Med 2013; 54:173-175
67. 18F-FDG PET/CT imaging for detection of malignancy. Eur J Nucl Med Mol Imaging 2012; 39:262-270
68. 18F-fluoride ion PET bone scanning. AJR 2006; 186:1783-1786
69. 18F-FDG PET/CT 1.0. Reston, VA: Society of Nuclear Medicine, 2006